Opus Genetics, Inc.: Caligan Partners LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Caligan Partners LP amended its Schedule 13G filing on Opus Genetics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001727492-26-000027. The filing signals a change in the investment firm's position in the clinical-stage gene therapy company, though the amended document did not disclose the revised share count or percentage in the headline. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts past the 5% threshold, making the update a marker of shifting institutional interest in the small-cap biotech. Investors will watch for the full filing details to gauge whether Caligan increased or trimmed its stake, and for any subsequent 13D filing that would indicate a more active posture toward Opus management.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Caligan Partners LP, Opus Genetics, Inc.